Drug Development Services Market Report 2026

The drug development services market size has grown rapidly in recent years. It will grow from $28.09 billion in 2025 to $31.5 billion in 2026 at a compound annual growth rate (CAGR) of 12.2%. The growth in the historic period can be attributed to growth in r&d investments by pharma companies, increase in outsourcing of drug development services, rising prevalence of chronic and infectious diseases, stricter regulatory compliance requirements, advancements in molecular biology and in vitro testing.

The drug development services market size is expected to see rapid growth in the next few years. It will grow to $50.26 billion in 2030 at a compound annual growth rate (CAGR) of 12.4%. The growth in the forecast period can be attributed to adoption of ai and machine learning in drug discovery, expansion of biologics and personalized medicine pipelines, increasing demand for contract research organizations, integration of cloud-based clinical data management, growth in emerging markets for drug development services. Major trends in the forecast period include preclinical research expansion, regulatory affairs optimization, pharmacovigilance enhancement, clinical data management services growth, quality assurance and compliance services strengthening.

The growing emphasis on precision and personalized medicine is expected to drive the growth of the drug development services market going forward. Precision and personalized medicine refers to a healthcare approach that customizes medical treatments and interventions based on patients’ genetic profiles, clinical characteristics, and specific disease conditions. The focus on precision and personalized medicine is increasing due to advancements in genomic technologies that allow more accurate diagnosis and targeted treatment selection. Drug development services enable precision and personalized medicine by facilitating the design, testing, and validation of targeted therapies tailored to specific genetic, molecular, and patient-related disease factors. For instance, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the FDA approved 16 new personalized treatments for rare diseases in 2023, compared with six approvals in 2022. Therefore, the growing emphasis on precision and personalized medicine is driving the growth of the drug development services market.

Leading companies in the drug development services market are focusing on developing innovative solutions, such as science-driven formulation acceleration platforms, to streamline early-stage drug formulation and reduce time-to-market for complex drug candidates. Science-driven formulation acceleration platforms are integrated development programs that apply targeted technologies and structured protocols to rapidly optimize drug formulations and advance them toward clinical testing. For example, in May 2025, Aenova Group GmbH, a Germany-based pharmaceutical company, launched the Aenovation program to accelerate the early development of pharmaceutical formulations, especially for poorly soluble compounds that are challenging to progress through the pipeline. The program uses a three-step approach, including comprehensive API profiling and developability classification, rapid formulation and prototype selection using solubility enhancement technologies, and seamless transfer to GMP lab and pilot-scale manufacturing to deliver right-first-time results and materials for first-in-human trials more quickly. By addressing critical bioavailability challenges and enabling efficient formulation strategies, the Aenovation program helps pharma innovators, including biotech start-ups, bring innovative therapies closer to clinical phases with greater speed and resource efficiency.

In September 2025, Symeres B.V., a Netherlands-based pharmaceutical company, acquired DGr Pharma for an undisclosed amount. Through this acquisition, Symeres expanded its early-phase drug development services and regulatory expertise to offer a more integrated end-to-end development platform for biopharmaceutical clients. DGr Pharma is a Netherlands-based firm providing consulting and operational support for early-stage pharmaceutical development.

Major companies operating in the drug development services market are IQVIA Holdings Inc., Labcorp Drug Development, Lonza Group AG, SGS Life Sciences, ICON plc, Eurofins Scientific SE, PPD Inc., Syneos Health Inc., WuXi AppTec Co. Ltd., Catalent Inc., Charles River Laboratories International Inc., Parexel International Corporation, Samsung Biologics Co. Ltd., Medpace Holdings Inc., PRA Health Sciences Inc., Fujifilm Diosynth Biotechnologies, Recipharm AB, PCI Pharma Services Inc., Almac Group Limited, Evotec SE, Aenova Group GmbH, Rentschler Biopharma SE, BioReliance Corporation, Covance SE.

Tariffs have influenced the drug development services market by increasing the cost of imported laboratory equipment, reagents, and specialized chemicals essential for preclinical and clinical testing. The impact is most pronounced on drug metabolism, medicinal chemistry, and biological services segments, particularly in regions like North America and Europe that rely on imported materials. Some domestic service providers benefit from the shift toward local sourcing, creating opportunities for regional CROs and research institutes to expand service offerings.

Drug development services refer to specialized services that support the discovery, testing, regulatory approval, and commercialization of new pharmaceutical and biotechnology products. Its purpose is to accelerate the development of safe and effective drugs, reduce time-to-market, and ensure compliance with regulatory standards.

The primary types of drug development services include drug metabolism and pharmacokinetics, biological services, and medicinal chemistry. Drug metabolism and pharmacokinetics involve the study of how drugs are absorbed, distributed, metabolized, and excreted in the body, providing essential data for safe and effective drug development. These services support processes such as candidate validation, lead optimization, hit-to-lead identification, target validation, and target selection. They are applied across drug types including biologics, infectious disease diagnostics, and small molecules. The therapeutic areas covered include cardiovascular disease, digestive system disease, immune system and infectious diseases, neurology, oncology, and other therapeutic areas, and they are used by end users such as pharmaceutical companies, biotechnology companies, contract research organizations, and academic and research institutes.

The drug development services market includes revenues earned by entities through the preclinical research services, in vitro testing services, toxicology and safety assessment, clinical data management, biostatistics services, regulatory affairs and submission support, pharmacovigilance services, and quality assurance and compliance services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The drug development services market research report is one of a series of new reports that provides drug development services market statistics, including drug development services industry global market size, regional shares, competitors with a drug development services market share, detailed drug development services market segments, market trends and opportunities, and any further data you may need to thrive in the drug development services industry. This drug development services market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

This product will be delivered within 1-3 business days.